BicycleRD

Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Bicycles. Bicycles are synthetic short peptides constrained by a small molecule scaffold into two loops, combining the high affinity and specificity of antibodies with the pharmacokinetic properties of small molecules. The company's pipeline includes Bicycle Toxin Conjugates (BTCs), Bicycle Tumor-Targeted Immune Cell Agonists (TICAs), and radiopharmaceuticals targeting various solid tumors. Their lead candidate, BT8009, is a Nectin-4 targeting BTC currently in registrational trials for metastatic urothelial cancer. The company leverages its proprietary phage display platform to rapidly discover and optimize candidates across multiple therapeutic areas, including oncology and rare diseases.